AP BIOSCIENCES INC.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
AP BIOSCIENCES INC. primarily focuses on the development of early-stage drug candidates through to preclinical trials, utilizing drug design and its two existing technology platforms to individually develop distinct monoclonal or bispecific antibody drugs tailored to promising targets, mechanisms of action, and disease characteristics.
AP BIOSCIENCES INC. possesses two technology platforms, both of which were independently developed by AP BIOSCIENCES INC. with full patent ownership:
1. OmniMab Library (Fully Human Antibody Library)
2. Target-Directed T-Cell Activation 3T Platform (T-cube Bispecific Antibody Platform)
New Drug R&D Products:
1. IBI302 (Anti-VEGF and Anti-Complement Bifunctional Recombinant Protein)
2. AP505/B1962 (PD-L1 x VEGF Bispecific Antibody)
3. AP203 (PD-L1 x CD137 Fully Human Bispecific Antibody)
4. AP402 (HER2v x CD137 Fully Human Bispecific Antibody)
5. AP601 (CD73 x CD137 Fully Human Bispecific Antibody)
AP BIOSCIENCES INC. possesses two technology platforms, both of which were independently developed by AP BIOSCIENCES INC. with full patent ownership:
1. OmniMab Library (Fully Human Antibody Library)
2. Target-Directed T-Cell Activation 3T Platform (T-cube Bispecific Antibody Platform)
New Drug R&D Products:
1. IBI302 (Anti-VEGF and Anti-Complement Bifunctional Recombinant Protein)
2. AP505/B1962 (PD-L1 x VEGF Bispecific Antibody)
3. AP203 (PD-L1 x CD137 Fully Human Bispecific Antibody)
4. AP402 (HER2v x CD137 Fully Human Bispecific Antibody)
5. AP601 (CD73 x CD137 Fully Human Bispecific Antibody)
The content above was translated by Ai
Founded Year
2013
Unified Business No.
54326052
Status
Active
Number of Employees
7
Total Paid-in
Capital
975,311,600 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2023)、OTC listing(2026)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
AP BIOSCIENCES INC. was established in 2013 and is a clinical-stage bispecific antibody drug development company. Addressing current unmet medical needs, we develop a series of antibody and protein lead drugs through our proprietary technology platforms, focusing on specific disease-related targets to provide safe, effective, and cost-effective medicines.
The content above was translated by Ai
